Abstract:Abstract Funding Acknowledgements Type of funding sources: Public Institution(s). Main funding source(s): Slovak Research and Development Agency Medical Research Council Grant Necroptosis, a necrosis-like programmed cell death modality dependent on the activity of receptor-interacting protein kinase 3 (RIP3) and mixed lineage domain kinase domain-like pseudokinase (MLKL), plays a prominent role in mediating myocardial ischemia/reperfusion injury. However, the extent to which necroptosis contributes to such damage under short and long reperfusion has not been evaluated in detail. In Wistar rat hearts, subjected to global 30-min ischemia followed by an acute 10-min reperfusion period, with compromised cardiac function, no changes in the protein expression of the main necroptotic markers (pThr231/Ser232-RIP3, MLKL) were found. Likewise, the non-canonical pathways of necroptosis involving Ca2+/calmodulin dependent protein kinase II–mitochondrial permeability transition pore (CaMKII–mPTP) or phosphoglycerate mutase 5–dynamin-related protein 1 (PGAM5–Drp1) axes were unlikely affected by such short reperfusion. In contrast, hearts subjected to global 30-min ischemia followed by a prolonged 40-min reperfusion period exhibited worsened hemodynamic parameters what was accompanied by the increased levels of RIP3, pSer229-RIP3 and MLKL. Moreover, this reperfusion period induced MLKL translocation to the plasma membrane, indicating necroptosis execution with resultant very likely cell disruption. Similarly, activated necroptosis, evidenced by the higher levels of proteins of the canonical pathway, has been suggested to contribute to the pathogenesis of post-infarction heart failure (30-min ischemia, 42-day reperfusion). Collectively, these findings suggest that short reperfusion seems to be insufficient to induce necroptosis in the heart and the molecular mechanisms being activated during the longer reperfusion phase are needed to promote necroptotic cell dying. Therefore, inhibition of necroptosis might represent a cardioprotective strategy in the settings of chronic, but not acute myocardial ischemia/reperfusion injury.

Relevance of necroptosis in the hearts subjected to acute versus chronic ischemia/reperfusion injury

Inhibition of Receptor-Interacting Protein 3 Upregulation and Nuclear Translocation Involved in Necrostatin-1 Protection Against Hippocampal Neuronal Programmed Necrosis Induced by Ischemia/reperfusion Injury.

The regulation of necroptosis and perspectives for the development of new drugs preventing ischemic/reperfusion of cardiac injury

RIP3 induces ischemic neuronal DNA degradation and programmed necrosis in rat via AIF

Inhibition of Cardiac RIP3 Mitigates Early Reperfusion Injury and Calcium-Induced Mitochondrial Swelling without Altering Necroptotic Signalling

Necroptosis in renal ischemia/reperfusion injury: A major mode of cell death?

Pleiotropic, non-cell death-associated effects of inhibitors of receptor-interacting protein kinase 1 in the heart

Dynamics of necroptosis in kidney ischemia-reperfusion injury

Abstract P336: Endogenous Alpha-1a Adrenergic Receptors Promote Cardiomyocyte Survival Through Suppression Of Rip Kinase-mediated Necroptosis

Necroptosis is a key mediator of enterocytes loss in intestinal ischaemia/reperfusion injury.

Abstract 17281: Programmed Necrosis of Ventricular Myocytes During Ischemic Stress Involves a Mitochondrial Regulated Bnip3- RIP-1- Cyclophilin D Signaling Pathway

Necroptosis: Mechanisms and Relevance to Disease.

RNA-seq based transcriptomic map reveals multiple pathways of necroptosis in treating myocardial ischemia reperfusion injury

Programmed Necrosis in Heart Disease: Molecular Mechanisms and Clinical Implications.

Necroptosis in health and diseases

[Programmed Necrosis: a New Target for Ischemia Reperfusion Injury].

Inhibition of Phosphoglycerate Mutase 5 Reduces Necroptosis in Rat Hearts Following Ischemia/Reperfusion Through Suppression of Dynamin-Related Protein 1

CaMKII is a RIP3 Substrate Mediating Ischemia- and Oxidative Stress–induced Myocardial Necroptosis

Pharmaceutical Therapies for Necroptosis in Myocardial Ischemia–Reperfusion Injury

Necroptosis Mediated by Impaired Autophagy Flux Contributes to Adverse Ventricular Remodeling after Myocardial Infarction

Inhibitory effect of melatonin on necroptosis via repressing the Ripk3-PGAM5-CypD-mPTP pathway attenuates cardiac microvascular ischemia reperfusion injury.